Audentes Therapeutics is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases through the application of adeno-associated virus gene therapy technology.
We have four programs in our pipeline:
- AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM). For more information about XLMTM, please go here.
- AT342 for the treatment of Crigler-Najjar Syndrome (CN).
- AT307 for the treatment of CASQ2-related Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), For more information about CASQ2-related CPVT, please go here.
- AT982 for the treatment of Pompe disease. For more information about Pompe disease, please go here.